Clinical Data ECO 2026: gut hormone signals differ in T1D with obesity Pharmaceutical TechnologyAt ECO 2026, researchers presented a study assessing fasting PYY, ghrelin and GIP levels in T1D patients, with or without obesity.Metabolic & GLP-1Read full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology At ECO 2026, researchers presented a study assessing fasting PYY, ghrelin and GIP levels in T1D patients, with or without obesity. Metabolic & GLP-1 Read full story Post navigation Previous: Zydus to acquire Assertio in $166m dealNext: Regulatory round-up: A month of key FDA approvals for cancer drugs Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
